bicalutamide has been researched along with Atherogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| López, MA; Morote, J; Placer, J; Planas, J; Raventós, C; Ropero, J; Salvador, C | 1 |
| Agreda, F; Lopez, MA; Morote, J; Placer, J; Planas, J; Salvador, C; Trilla, E | 1 |
2 other study(ies) available for bicalutamide and Atherogenesis
| Article | Year |
|---|---|
[Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Atherosclerosis; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Humans; Lipoproteins; Male; Nitriles; Prostate; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk; Tosyl Compounds; Triglycerides; Triptorelin Pamoate | 2012 |
Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Atherosclerosis; Biomarkers; Cholesterol; Gonadotropin-Releasing Hormone; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds; Treatment Outcome; Triglycerides | 2013 |